April 15, 2021
GEXVal Presented at MINERVA Business Plan Presentation
President and CEO of GEXVal, Juran Kato presented GEXVal’s Business at the MINERVA Business Plan Presentation held on April 13, 2021.
Today, there are more than 7,000 known rare diseases, and it is estimated that 1 in 10 people are affected by some rare disease.1）
GEXVal is focusing early stage clinical development for rare disease therapeutics with new chemical entity licensed major from pharmaceutical companies.
Launched in 2000 by a private company in collaboration with Kanagawa Prefecture, it has
developed into an open platform to support venture businesses.
1）EvaluatePharma®, 2018, Orphan Drug Report 2018, 5thEdition
For future information, please contact us: firstname.lastname@example.org